CoChat

The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity

Open access
Amadori, Céline, van der Velden, Yme Ubeles, Bonnard, Damien, Orlov, Igor, van Bel, Nikki, Le Rouzic, Erwann, Miralles, Laia, Brias, Julie, Chevreuil, Francis, Spehner, Daniele, Chasset, Sophie, Ledoussal, Benoit, Mayr, Luzia, Moreau, François, García, Felipe, Gatell, José, Zamborlini, Alessia, Emiliani, Stéphane, Ruff, Marc, Klaholz, Bruno P., Moog, Christiane, Berkhout, Ben, Plana, Montserrat, Benarous, Richard · 2017 · Retrovirology

The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.

Abstract

HIV-1 Integrase (IN) interacts with the cellular co-factor LEDGF/p75 and tethers the HIV preintegration complex to the host genome enabling integration. Recently a new class of IN inhibitors was described, the IN-LEDGF allosteric inhibitors (INLAIs). Designed to interfere with the IN-LEDGF interaction during integration, the major impact of these inhibitors was surprisingly found on virus maturation, causing a reverse transcription defect in target cells. Here we describe the MUT-A compound as a genuine INLAI with an original chemical structure based on a new type of scaffold, a thiophene ring. MUT-A has all characteristics of INLAI compounds such as inhibition of IN-LEDGF/p75 interaction, IN multimerization, dual antiretroviral (ARV) activities, normal packaging of genomic viral RNA and complete Gag protein maturation. MUT-A has more potent ARV activity compared to other INLAIs previously reported, but similar profile of resistance mutations and absence of ARV activity on SIV. HIV-1 virions produced in the presence of MUT-A were non-infectious with the formation of eccentric condensates outside of the core. In studying the immunoreactivity of these non-infectious virions, we found that inactivated HIV-1 particles were captured by anti-HIV-specific neutralizing and non-neutralizing antibodies (b12, 2G12, PGT121, 4D4, 10-1074, 10E8, VRC01) with efficiencies comparable to non-treated virus. Autologous CD4+ T lymphocyte proliferation and cytokine induction by monocyte-derived dendritic cells (MDDC) pulsed either with MUT-A-inactivated HIV or non-treated HIV were also comparable. Although strongly defective in infectivity, HIV-1 virions produced in the presence of the MUT-A INLAI have a normal protein and genomic RNA content as well as B and T cell immunoreactivities comparable to non-treated HIV-1. These inactivated viruses might form an attractive new approach in vaccine research in an attempt to study if this new type of immunogen could elicit an immune response against HIV-1 in animal models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12977-017-0373-2

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Structure, biochemical and antiretroviral activities of MUT-A. a Chemical structure of MUT-A. b Titration of MUT-A ARV activity on HIV-1 NL4-3 and HxB2 strains in MT4 cell infection assay. c Biochemical activities of MUT-A on IN-LEDGF/p75 interaction (IC50) and of IN multimerization (activation concentration AC50 and maximum signal increase plateau). d EC50 of ARV activities of MUT-A and references HIV-1 NL4-3 and HxB2 strains in MT4 cell infection assay. DTG: INSTI Dolutegravir. e–g Correlations between IN multimerization (IN–IN) AC50 and IN-LEDGF/p75 IC50 (e), ARV EC50 and IN-LEDGF IC50 (f), ARV EC50s and IN–IN AC50s (g) of MUT-A compound series
Fig. 1 Structure, biochemical and antiretroviral activities of MUT-A. a Chemical structure of MUT-A. b Titration of MUT-A ARV activity on HIV-1 NL4-3 and HxB2 strains in MT4 cell infection assay. c Biochemical activities of MUT-A on IN-LEDGF/p75 interaction (IC50) and of IN multimerization (activation concentration AC50 and maximum signal increase plateau). d EC50 of ARV activities of MUT-A and references HIV-1 NL4-3 and HxB2 strains in MT4 cell infection assay. DTG: INSTI Dolutegravir. e–g Correlations between IN multimerization (IN–IN) AC50 and IN-LEDGF/p75 IC50 (e), ARV EC50 and IN-LEDGF IC50 (f), ARV EC50s and IN–IN AC50s (g) of MUT-A compound seriesCC BY · PubMed Central
Fig. 2 Resistance profile of MUT-A. a Comparative resistance profile of MUT-A and references (EVG, BI-D and BI-224436). The color code subdivides the fold change in resistance into five levels of magnitude. b Long-term culture of infected MT4 cells with escalating concentrations of drugs. Cells were initially infected at 0.005 MOI with HIV-1 and were passaged twice weekly in the presence of RAL (filled circle), NVP (filled diamond), or MUT-A (filled upward triangle). The serial passage was carried out over 67 days. The highest concentration of compounds at which the virus could replicate in culture are shown. Error bars represent the variation obtained in one experiment done in triplicate. c Frequency of mutations in IN sequences. Cloned sequences were analyzed at day 23, 43 and 67 from 30 to 40 individual clones (% of total clones analyzed)
Fig. 2 Resistance profile of MUT-A. a Comparative resistance profile of MUT-A and references (EVG, BI-D and BI-224436). The color code subdivides the fold change in resistance into five levels of magnitude. b Long-term culture of infected MT4 cells with escalating concentrations of drugs. Cells were initially infected at 0.005 MOI with HIV-1 and were passaged twice weekly in the presence of RAL (filled circle), NVP (filled diamond), or MUT-A (filled upward triangle). The serial passage was carried out over 67 days. The highest concentration of compounds at which the virus could replicate in culture are shown. Error bars represent the variation obtained in one experiment done in triplicate. c Frequency of mutations in IN sequences. Cloned sequences were analyzed at day 23, 43 and 67 from 30 to 40 individual clones (% of total clones analyzed)CC BY · PubMed Central
Fig. 3 Antiviral activity in infection assays with HIV-1 and SIV. Dose–response curves for RAL (a), BI-D (b) and MUT-A (c) activity in MT4 cells infected with either HIV-1 NL4-3 (filled upward triangle) or SIVmac239 (filled circle). Error bars represent the variation obtained from three independent experiments done in duplicate
Fig. 3 Antiviral activity in infection assays with HIV-1 and SIV. Dose–response curves for RAL (a), BI-D (b) and MUT-A (c) activity in MT4 cells infected with either HIV-1 NL4-3 (filled upward triangle) or SIVmac239 (filled circle). Error bars represent the variation obtained from three independent experiments done in duplicateCC BY · PubMed Central
Fig. 4 Immunoreactivity of HIV-1 produced in the presence or absence of MUT-A. a Schematic of the antibody capture assay of native HIV-1 particles produced. The capacity of the different antibodies to capture native HIV-1 particles was assessed by ELISA. HIV-1 particles retained by the antibodies were lysed and quantified by CA-p24 detection by ELISA. b The different monoclonal and polyclonal antibodies used in virus-capture assays are listed together with their specific target and their ability to neutralize HIV-1. Nonspecific antibodies (polyclonal IgG HIV- and mAb Syn = Synagis) were used as negative controls. c Quantitation by CA-p24 ELISA of native HIV-1 particles produced in the presence (red bars) or absence (blue bars) of MUT-A that have been captured with the different antibodies used at three different concentrations
Fig. 4 Immunoreactivity of HIV-1 produced in the presence or absence of MUT-A. a Schematic of the antibody capture assay of native HIV-1 particles produced. The capacity of the different antibodies to capture native HIV-1 particles was assessed by ELISA. HIV-1 particles retained by the antibodies were lysed and quantified by CA-p24 detection by ELISA. b The different monoclonal and polyclonal antibodies used in virus-capture assays are listed together with their specific target and their ability to neutralize HIV-1. Nonspecific antibodies (polyclonal IgG HIV- and mAb Syn = Synagis) were used as negative controls. c Quantitation by CA-p24 ELISA of native HIV-1 particles produced in the presence (red bars) or absence (blue bars) of MUT-A that have been captured with the different antibodies used at three different concentrationsCC BY · PubMed Central
Fig. 5 T-cell proliferation induced by autologous MDDCs exposed to MUT-A-inactivated HIV-1 assessed by CFSE proliferation assay. Proliferation in response to autologous MDDCs exposed to wt HIV-1 (NL4-3 DMSO) or MUT-A or AT-2 inactivated HIV-1 in a 6-day co-culture was assessed in triplicates using the CFSE proliferation assay. MDDCs were pulsed with virus particles corresponding to 1 μg/mL of HIV-1 Gag CA-p24. A representative (out of 3 independent experiments) flow cytometry dot plots showing lymphocyte gating strategy by FSC/SSC and CD3+ positive staining, as well as dot plots showing CFSE dilution in gated CD3+ CD4+ T lymphocytes after in vitro stimulation with the above mentioned virus or negative (medium) and positive SEA controls
Fig. 5 T-cell proliferation induced by autologous MDDCs exposed to MUT-A-inactivated HIV-1 assessed by CFSE proliferation assay. Proliferation in response to autologous MDDCs exposed to wt HIV-1 (NL4-3 DMSO) or MUT-A or AT-2 inactivated HIV-1 in a 6-day co-culture was assessed in triplicates using the CFSE proliferation assay. MDDCs were pulsed with virus particles corresponding to 1 μg/mL of HIV-1 Gag CA-p24. A representative (out of 3 independent experiments) flow cytometry dot plots showing lymphocyte gating strategy by FSC/SSC and CD3+ positive staining, as well as dot plots showing CFSE dilution in gated CD3+ CD4+ T lymphocytes after in vitro stimulation with the above mentioned virus or negative (medium) and positive SEA controlsCC BY · PubMed Central
Fig. 6 CD4+ and CD8+ T-cell proliferation induced by autologous MDDCs exposed to MUT-A-inactivated HIV-1. a Proliferation in response to autologous MDDC exposed to wt HIV-1 (NL4-3 DMSO) or MUT-A inactivated HIV-1 or AT-2-inactivated HIV-1 in a 6-day co-culture was assessed in triplicates using the CFSE proliferation assay. MDDCs were pulsed with either 5 μg/mL HIV-1 (NL4-3 DMSO or MUT-A) or 1 μg/mL HIV-1 (NL4-3 AT-2) of HIV-1 gag CA-p24. A representative (out of three independent experiments) flow cytometry dot plots showing CFSE dilution in gated CD3+ CD4+ and CD3+ CD8+ T lymphocytes after in vitro stimulation with the above mentioned viruses or negative (medium) and positive SEA controls. b, c Quantitation of T CD4+ (B) and CD8+ (C) proliferation in response to autologous MDDC exposed to wt HIV virus (NL4-3 DMSO) or inactivated HIV virus (MUT-A or NL4-3 AT-2) in a 6-day co-culture was assessed in triplicates using the CFSE proliferation assay. In all viruses used, MDDCs were pulsed with 1 µg/mL of HIV gag CA-p24. Graph showing mean ± SD of percentages of CFSE low CD3+ CD4+ (b) and CD3+ CD8+ (c) T cells from three different co-cultures are represented
Fig. 6 CD4+ and CD8+ T-cell proliferation induced by autologous MDDCs exposed to MUT-A-inactivated HIV-1. a Proliferation in response to autologous MDDC exposed to wt HIV-1 (NL4-3 DMSO) or MUT-A inactivated HIV-1 or AT-2-inactivated HIV-1 in a 6-day co-culture was assessed in triplicates using the CFSE proliferation assay. MDDCs were pulsed with either 5 μg/mL HIV-1 (NL4-3 DMSO or MUT-A) or 1 μg/mL HIV-1 (NL4-3 AT-2) of HIV-1 gag CA-p24. A representative (out of three independent experiments) flow cytometry dot plots showing CFSE dilution in gated CD3+ CD4+ and CD3+ CD8+ T lymphocytes after in vitro stimulation with the above mentioned viruses or negative (medium) and positive SEA controls. b, c Quantitation of T CD4+ (B) and CD8+ (C) proliferation in response to autologous MDDC exposed to wt HIV virus (NL4-3 DMSO) or inactivated HIV virus (MUT-A or NL4-3 AT-2) in a 6-day co-culture was assessed in triplicates using the CFSE proliferation assay. In all viruses used, MDDCs were pulsed with 1 µg/mL of HIV gag CA-p24. Graph showing mean ± SD of percentages of CFSE low CD3+ CD4+ (b) and CD3+ CD8+ (c) T cells from three different co-cultures are representedCC BY · PubMed Central
Fig. 7 Secretion of IL-12, IFN-γ, IL2-R and MIP-1β induced by autologous MDDCs exposed to MUT-A-inactivated HIV-1. Cytokine and chemokine secretion in response to autologous MDDCs exposed to wt HIV-1 (NL4-3 DMSO) or MUT-A-inactivated HIV-1 (MUT-A 1 µM) in supernatants from a 6-day co-culture was assessed in duplicates by Luminex assay. Graph representing mean ± SD concentrations (pg/mL) of IL-12 (a), IFN-γ (b), IL2-R (c), and MIP-1β (d) analyzed after three different co-cultures
Fig. 7 Secretion of IL-12, IFN-γ, IL2-R and MIP-1β induced by autologous MDDCs exposed to MUT-A-inactivated HIV-1. Cytokine and chemokine secretion in response to autologous MDDCs exposed to wt HIV-1 (NL4-3 DMSO) or MUT-A-inactivated HIV-1 (MUT-A 1 µM) in supernatants from a 6-day co-culture was assessed in duplicates by Luminex assay. Graph representing mean ± SD concentrations (pg/mL) of IL-12 (a), IFN-γ (b), IL2-R (c), and MIP-1β (d) analyzed after three different co-culturesCC BY · PubMed Central
Fig. 8 IL-5, IL-6, IL-10, IL-13, MIP-1α, MCP-1 and IP-10 secretion induced by MUT-A-HIV-1-exposed autologous MDDCs. Cytokine and chemokine secretion in response to autologous MDDCs exposed to wt HIV-1 (NL4-3 DMSO) or MUT-A-inactivated HIV-1 (MUT-A 1 µM) in supernatants from a 6-day co-culture was assessed in duplicates by Luminex assay. Graph representing mean ± SD concentrations (pg/mL) of IL-10 (a), IL-6 (b), IL-13 (c), MIP-1α (d), MCP-1 (e), IL-5 (f) and IP-10 (g) analyzed after three different co-cultures
Fig. 8 IL-5, IL-6, IL-10, IL-13, MIP-1α, MCP-1 and IP-10 secretion induced by MUT-A-HIV-1-exposed autologous MDDCs. Cytokine and chemokine secretion in response to autologous MDDCs exposed to wt HIV-1 (NL4-3 DMSO) or MUT-A-inactivated HIV-1 (MUT-A 1 µM) in supernatants from a 6-day co-culture was assessed in duplicates by Luminex assay. Graph representing mean ± SD concentrations (pg/mL) of IL-10 (a), IL-6 (b), IL-13 (c), MIP-1α (d), MCP-1 (e), IL-5 (f) and IP-10 (g) analyzed after three different co-culturesCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 24

Metadata

Authors
Amadori, C., van der Velden, Y. U., Bonnard, D., Orlov, I., van Bel, N., Le Rouzic, E., Miralles, L., Brias, J., Chevreuil, F., Spehner, D., Chasset, S., Ledoussal, B., Mayr, L., Moreau, F., García, F., Gatell, J., Zamborlini, A., Emiliani, S., Ruff, M., Klaholz, B. P., Moog, C., Berkhout, B., Plana, M., & Benarous, R.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Mutabilis (France) (FR)
  • Hospital Clínic de Barcelona (ES)
  • Inserm (FR)
  • Conservatoire National des Arts et Métiers (FR)
  • Amsterdam UMC Location University of Amsterdam (NL)
Corresponding author
  • Berkhout, Ben
  • Plana, Montserrat
Venue
Retrovirology
Published
2017-11-09
Volume
14
Issue
1
Pages
50-50
ISSN
1742-4690 (ISSN-L)
OpenAlex
W2767587886
Cited by
22
References
45
Citations by year
2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 4
FWCI
1.47
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Retrovirology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • European Commission (305137)
  • Agence Nationale de la Recherche (ANR-10-INSB-05-01., 10-INSB-05-01, ANR- 10-INSB-05, ANR-10, ANR-10-INBS-0005)
  • Association Nationale de la Recherche et de la Technologie
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (016.Veni.171.112)
  • French Infrastructure for Integrated Structural Biology (ANR-10- INSB-05, ANR-10-INSB-0501, INSB-05)
  • National Institutes of Health
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
HIV-1 integrase, LEDGF/p75, allosteric inhibitors, antiretroviral resistance, virus maturation, viral infectivity, RNA packaging, Gag protein, immunoreactivity, neutralizing antibodies, simian immunodeficiency virus
MeSH terms
Cell Line, Humans, Pyridines, Thiophenes, Virus Replication, HIV Antibodies, HIV-1, Virus Integration, Virus Assembly, HIV Integrase, HIV Integrase Inhibitors, Intercellular Signaling Peptides and Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. https://app.cochat.ai/papers/10.1186/s12977-017-0373-2
The paper
Amadori, C., van der Velden, Y. U., Bonnard, D., Orlov, I., van Bel, N., Le Rouzic, E., Miralles, L., Brias, J., Chevreuil, F., Spehner, D., Chasset, S., Ledoussal, B., Mayr, L., Moreau, F., García, F., Gatell, J., Zamborlini, A., Emiliani, S., Ruff, M., . . . Benarous, R. (2017). The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity. Retrovirology. https://doi.org/10.1186/s12977-017-0373-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.